Articles
Improvements in quality and bioequivalence policies in Latin America

Improvements in quality and bioequivalence policies in Latin...

Dr Timothy Riley discusses how the commercial opportunities in the emerging market of Latin America are affected by pressures on lowering healthcare costs and tougher regulations. Latin America countries are viewed by much of the pharmaceutical industry as an emerging market that offers...

Articles
Orphan drug repositioning – to or from a more common disease?

Orphan drug repositioning – to or from a more common disease...

In our rare disease focus month, Caroline Mathie looks at whether it is more beneficial for pharma to reposition a drug from a common disease to a rare disease, or vice versa. Finding new uses for known drug compounds is a strategy well recognised by the industry for both...

Articles
The NHS in 2013: the new leaders of healthcare – who are they?

The NHS in 2013: the new leaders of healthcare – who are the...

Anthony Rowbottom discusses the introduction of the Health and Social Care Act 2012, which is set to transform the healthcare landscape from April 2013. A lot has been written about David Bennett, most notably his connections to McKinsey. Indeed, critics of the...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D